Syringe

Europe Syringes & Needles Insights Report 2023: A $7.97 Billion Market in 2022 - Forecasts to 2028 with BD, CardinalHealth, B Braun, Nipro, and Terumo Dominating - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023
Medical Supplies, Health, Syringe, Research, Conditional sentence, Incidence, Element, B. Braun, Lead, Growth, Hospital, Diabetes, Video game, Needle

The "Europe Syringes & Needles Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Syringes & Needles Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive report delves into the intricacies of the syringes and needles market in Europe, covering the period from 2023 to 2028.
  • It provides an extensive overview of various factors that are propelling the market growth, alongside potential restraints and emerging trends.
  • Key players like BD, CardinalHealth, B Braun, Nipro, and Terumo Corp are at the forefront of the European syringes & needles market.

United States Syringes & Needles Market Insights Report 2023: A $10.87 Billion Market by 2028 with BD, ICU Medical, Nipro Medical, Terumo, and Cardinal Health Emerging as Prominent Players - ResearchAndMarkets.com

Retrieved on: 
Monday, December 11, 2023
Medical Supplies, Health, Nipro, Sale, Syringe, Fungal infection, Conditional sentence, Incidence, ICU Medical, Cardinal Health, Hospital, Needle, Vaccination, Vaccine, Immunization, Cardinal, Diabetes, Anthrax Vaccine Immunization Program

This report offers market size & forecast data for the US syringes & needles market.

Key Points: 
  • This report offers market size & forecast data for the US syringes & needles market.
  • This report provides a comprehensive and current market scenario of the US syringes & needles market, including the US syringes & needles market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present US syringes & needles market and its market dynamics for 2023?2028.
  • BD, ICU Medical, Nipro Corporation, Terumo, and Cardinal Health are the key players in the US syringes and needles market.

Sol-Millennium Follow-up Response to FDA Communication

Retrieved on: 
Thursday, December 7, 2023
Infectious Diseases, FDA, Health, Medical Supplies, Syringe, Communication, Safety, ISO, Quality assurance, Medical device

The FDA issued a Safety Communication on November 30, 2023, stating concerns that certain plastic syringes made in China may not provide consistent and adequate quality or performance.

Key Points: 
  • The FDA issued a Safety Communication on November 30, 2023, stating concerns that certain plastic syringes made in China may not provide consistent and adequate quality or performance.
  • Sol-Millennium users can continue to trust that Sol-Millennium’s syringes will function as intended, as the FDA safety notice does not apply to any Sol-Millennium products.
  • Sol-Millennium manufacturing locations in China adhere to stringent sampling techniques for raw material, in-process inspections, and final inspections prior to product release.
  • Please reach out to local Sol-Millennium representative or contact Sol-Millennium customer service at [email protected] or 833-637-0857 with any questions.

Retractable Technologies, Inc. Not Impacted by FDA Safety Communication

Retrieved on: 
Friday, December 1, 2023
General Health, Medical Devices, Other Health, Health, Medical Supplies, Potential, Syringe, Safety, NYSE, FDA, Communication, RVP, Medical device, Vaccine

Retractable Technologies, Inc. (NYSE American: RVP) reports that the FDA Safety Communication “Evaluating Plastic Syringes Made in China for Potential Device Failures” on November 30, 2023 does not refer to syringes from Retractable Technologies Inc.

Key Points: 
  • Retractable Technologies, Inc. (NYSE American: RVP) reports that the FDA Safety Communication “Evaluating Plastic Syringes Made in China for Potential Device Failures” on November 30, 2023 does not refer to syringes from Retractable Technologies Inc.
  • The FDA identified quality issues related to “leaks, breakage, and other problems after manufacturers made changes to the syringe dimensions.” Retractable Technologies has not incorporated any recent changes to the dimensions of the syringe barrel on its gold-standard VanishPoint Safety Syringe.
  • VanishPoint users can continue to be confident not only in VanishPoint’s ability to deliver the correct dose of medication, but also in its ability to protect users from needlesticks better than any other safety syringe.
  • If you have any question or concerns about the FDA Safety Communication, please do not hesitate to contact us.

Sol-Millennium Responds to FDA Safety Communication

Retrieved on: 
Saturday, December 2, 2023
Medical Supplies, Health, FDA, Medical Devices, Infectious Diseases, Other Health, General Health, Communication, Syringe, Needle, Patient, COVID-19, Multimedia, ISO, Quality assurance, Medical device

Sol-Millennium, manufacturer of medical devices, including syringes for medicine delivery and testing, issued a statement regarding the FDA’s November 30 Safety Communication regarding syringes manufactured in China.

Key Points: 
  • Sol-Millennium, manufacturer of medical devices, including syringes for medicine delivery and testing, issued a statement regarding the FDA’s November 30 Safety Communication regarding syringes manufactured in China.
  • The communication does not list manufacturers.
  • Sol-Millennium's manufacturing partners based in China adhere to stringent sampling techniques for raw material, in-process, and final inspections prior to product release.
  • Sol-Millennium seeks to reassure its customers and their patients that the firm places safety and reliability at the top of its concerns and efforts.

Stevanato Group's Mavis™ Combi Visual Inspection Machine Selected as Pharma Innovation Award Winner by Pharma Manufacturing

Retrieved on: 
Thursday, November 16, 2023
Health, Medical Devices, Other Science, Research, Science, Pharmaceutical, Biotechnology, Syringe, Glass, Safety, NYSE, Stevanato Group, Multimedia, Combi, Quality control, Endeavor Business Media, Engineering, Pharma, Fine chemical

View the full release here: https://www.businesswire.com/news/home/20231116606597/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231116606597/en/
    Stevanato Group's Mavis™ Combi machine for visual inspection.
  • The Mavis™ Combi visual inspection line is a cutting-edge solution designed to provide advanced performance, flexibility, and speed to enhance visual inspection of primary packaging and the drugs within it.
  • The Mavis™ Combi is part of Stevanato Group's Mavis™ platform, which also includes equipment for visual inspection of syringes.
  • “It's a privilege to be acknowledged for the innovation behind the Mavis™ Combi visual inspection line,” said Paolo Superchi, Vice President of Engineering Operations at Stevanato Group.

KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Syringe, Real, Attack, Asthma, Lung compliance, Patient, Division, American College, Internal medicine, Hereditary angioedema, Anxiety, KALV, HAE, University, Pain, University of California, Freie Berliner Kunstausstellung, ACAAI, Rheumatology, Immunology

“We continue to learn from people living with HAE that currently available parenteral on-demand treatments are simply not meeting their needs,” said Andrew Crockett, Chief Executive Officer of KalVista.

Key Points: 
  • “We continue to learn from people living with HAE that currently available parenteral on-demand treatments are simply not meeting their needs,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • “Whether this is related to always carrying their syringes or vials, challenges in preparing and administering injectable or infused treatments outside the home, or anxiety related to potential injection-site reactions and pain, patients struggle to follow treatment guidelines.
  • This can lead to non-compliance and preference for long-term prophylaxis, even in cases where on-demand treatments would otherwise suffice.
  • We also note that despite the use of long-term prophylaxis, HAE patients require HAE-related home health visits and seek ER treatment more often than would be expected.

Guerbet announces marketing authorisation approval of Elucirem™ (Gadopiclenol) in the European Union

Retrieved on: 
Monday, December 11, 2023
Syringe, Safety, Regulatory affairs, European Medicines Agency, Aulnay-sous-Bois, European Commission, Ageing, GBCA, Gadolinium, Civil service commission, Medicine, European, FDA, CHMP, BBB, Marketing, Committee, Pathology, Marans, Charente-Maritime, Person, Medical imaging, Seine-Saint-Denis, MRI, Radiology

The marketing authorisation (MA) for Elucirem™ (Gadopiclenol) was granted to Guerbet by the European Commission based on the positive opinion of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dated 12 October 2023.

Key Points: 
  • The marketing authorisation (MA) for Elucirem™ (Gadopiclenol) was granted to Guerbet by the European Commission based on the positive opinion of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dated 12 October 2023.
  • It will be marketed by Guerbet in the European Union in the following forms: vials and prefilled syringes.
  • "After its approval by the FDA for the American market, the European marketing authorisation for Elucirem™ reinforces our strategic perspective: combining medical innovation and environmental commitment.
  • This authorisation is ground-breaking for Medical Imaging in Europe," concludes David Hale, Guerbet CEO.

Pharmaceutical Glass Tubing Market to Reach US$ 11.2 Billion by 2030, Rising at a CAGR of 7.1% | Report by CoherentMI

Retrieved on: 
Monday, December 11, 2023
Syringe, Glass, Precision glass moulding, Thermo Fisher Scientific, Safety, Research, Conditional sentence, Prevalence, Collection, Biotechnology, Traction, Division, A, Laboratory, Medication, Blood, SGD, Schott AG, Growth, Corning Inc., Transport, Borosilicate glass, Fine chemical, Vaccine, Distribution (marketing), Chemical, Pharmaceutical industry, Corning

This helps in ensuring the safety and efficacy of pharmaceutical products, thereby driving the demand for pharmaceutical glass tubing.

Key Points: 
  • This helps in ensuring the safety and efficacy of pharmaceutical products, thereby driving the demand for pharmaceutical glass tubing.
  • Glass tubing plays a crucial role in the packaging and delivery of these drugs, thus increasing the demand for pharmaceutical glass tubing.
  • The market opportunity in the pharmaceutical glass tubing industry stems from the increasing demand for glass tubing in the pharmaceutical sector.
  • North America is expected to dominate the pharmaceutical glass tubing market, attributed to the presence of established pharmaceutical companies and research organizations in the region.

Pharmaceutical Glass Tubing Market to Reach US$ 11.2 Billion by 2030, Rising at a CAGR of 7.1% | Report by CoherentMI

Retrieved on: 
Monday, December 11, 2023
Syringe, Glass, Precision glass moulding, Thermo Fisher Scientific, Safety, Research, Conditional sentence, Prevalence, Collection, Biotechnology, Traction, Division, A, Laboratory, Medication, Blood, SGD, Schott AG, Growth, Corning Inc., Transport, Borosilicate glass, Fine chemical, Vaccine, Distribution (marketing), Chemical, Pharmaceutical industry, Corning

This helps in ensuring the safety and efficacy of pharmaceutical products, thereby driving the demand for pharmaceutical glass tubing.

Key Points: 
  • This helps in ensuring the safety and efficacy of pharmaceutical products, thereby driving the demand for pharmaceutical glass tubing.
  • Glass tubing plays a crucial role in the packaging and delivery of these drugs, thus increasing the demand for pharmaceutical glass tubing.
  • The market opportunity in the pharmaceutical glass tubing industry stems from the increasing demand for glass tubing in the pharmaceutical sector.
  • North America is expected to dominate the pharmaceutical glass tubing market, attributed to the presence of established pharmaceutical companies and research organizations in the region.